- Home
- ATYR vs CRNT Comparison
ATYR vs CRNT Comparison
Compare ATYR & CRNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATYR
- CRNT
- Stock Information
- Founded
- ATYR 2005
- CRNT 1996
- Country
- ATYR United States
- CRNT Israel
- Employees
- ATYR N/A
- CRNT N/A
- Industry
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- CRNT Radio And Television Broadcasting And Communications Equipment
- Sector
- ATYR Health Care
- CRNT Technology
- Exchange
- ATYR Nasdaq
- CRNT Nasdaq
- Market Cap
- ATYR 290.6M
- CRNT 186.7M
- IPO Year
- ATYR 2015
- CRNT 2000
- Fundamental
- Price
- ATYR $3.34
- CRNT $2.20
- Analyst Decision
- ATYR Strong Buy
- CRNT Strong Buy
- Analyst Count
- ATYR 6
- CRNT 5
- Target Price
- ATYR $18.60
- CRNT $5.85
- AVG Volume (30 Days)
- ATYR 1.1M
- CRNT 857.1K
- Earning Date
- ATYR 05-07-2025
- CRNT 05-07-2025
- Dividend Yield
- ATYR N/A
- CRNT N/A
- EPS Growth
- ATYR N/A
- CRNT 367.84
- EPS
- ATYR N/A
- CRNT 0.25
- Revenue
- ATYR N/A
- CRNT $394,344,000.00
- Revenue This Year
- ATYR $551.06
- CRNT $3.27
- Revenue Next Year
- ATYR $2,144.84
- CRNT $7.56
- P/E Ratio
- ATYR N/A
- CRNT $8.72
- Revenue Growth
- ATYR N/A
- CRNT 11.94
- 52 Week Low
- ATYR $1.42
- CRNT $1.95
- 52 Week High
- ATYR $4.66
- CRNT $5.73
- Technical
- Relative Strength Index (RSI)
- ATYR 51.21
- CRNT 45.31
- Support Level
- ATYR $3.06
- CRNT $2.03
- Resistance Level
- ATYR $3.67
- CRNT $2.43
- Average True Range (ATR)
- ATYR 0.25
- CRNT 0.11
- MACD
- ATYR 0.01
- CRNT 0.04
- Stochastic Oscillator
- ATYR 46.77
- CRNT 48.89
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
About CRNT Ceragon Networks Ltd.
Ceragon Networks Ltd is a wireless transport company in terms of unit shipments and global distribution of its business, providing high-capacity wireless connectivity solutions to global markets across various industries, mainly wireless (mobile) networks service providers. Geographically the company generates the major revenue from India. The company also has presence in North America, Europe, Africa, Asia-Pacific and Middle East, and Latin America. The company's products include IP-50 Platform, IP-20 Platform, Pointlink.